A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

One thing to know is that another drug called Zepbound contains the same active ingredient as Mounjaro — tirzepatide — and is FDA-approved for weight loss. Mounjaro is prescribed for those ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...